摘要
目的探讨尿脱氧吡啶啉(DPD)的检测对应用糖皮质激素治疗的哮喘患者骨吸收的诊断价值。方法采用酶免疫测定法检测50例应用糖皮质激素治疗超过半年的哮喘患者的尿DPD,其中吸入激素组36例,全身应用激素组14例,与同期非激素治疗的哮喘患者18例的尿DPD作比较。结果全身激素治疗组患者尿DPD值较吸入激素组、非激素治疗组显著增高(P<0.01),吸入激素与非激素治疗组尿DPD值无明显区别(P>0.05)。结论全身应用皮质激素治疗的哮喘患者骨吸收明显,吸入疗法对哮喘患者骨影响是安全的,尿DPD可作为糖皮质激素治疗哮喘患者对骨质影响的敏感指标。
Objective：To study evaluation of detection of urinary deoxypyridinoline for bone obsorption in asthma. Methods： The urinary deoxypyridinoline of 50 patients treated with glucocorticoid hormone for asthma over half a year was detected. Among the 50, patient 36 adopted the remedy of sucking hormone, 14 did the remedy of po or venoclysis, two remedies compared with the remedy of non-hormone that 18 patients who adopted in the same period of time. Results： DPD of the patients who adopted the remedy of glucocorticoid hormone po or venoclysis was higher than that of the others（P〈0.01）, DPD of patients who adopted the other two remedies is no obvious difference（P〉0. 05）. Conclusion. The remedy of sucking hormone is safe towards bone obsorption in the couse of asthma treatment,DPD can be used as a sensitive marker of bone change in the usage of glucocorticoid hormone to treat asthma.
出处
《实用临床医学（江西）》
CAS
2005年第8期22-23,共2页
Practical Clinical Medicine
关键词
尿脱氧吡啶啉
哮喘
糖皮质激素
骨吸收
urinary deoxypyridinoline
asthma
glucocorticoid hormone
bone absorption
